Stay updated on SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial

Sign up to get notified when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision: v3.4.3 implemented. No visible changes to study data, eligibility criteria, or study details.
    Difference
    0.0%
    Check dated 2026-03-08T13:36:57.000Z thumbnail image
  3. Check
    21 days ago
    No Change Detected
  4. Check
    35 days ago
    Change Detected
    Summary
    Revision label updated from v3.4.1 to v3.4.2; no study data or page functionality appears to be altered.
    Difference
    0.0%
    Check dated 2026-02-14T22:45:14.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Added Primary peritoneal carcinoma to the conditions, introduced a Resources section with the Genetic and Rare Diseases Information Center, and updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.2%
    Check dated 2026-02-07T17:13:19.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    Added Show glossary and Hide glossary controls, Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0; removed Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.
    Difference
    0.3%
    Check dated 2026-01-23T10:51:37.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    Revision updated from v3.3.3 to v3.3.4; no substantive changes to study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-16T06:44:37.000Z thumbnail image
  8. Check
    94 days ago
    Change Detected
    Summary
    Locations are reorganized under a new consolidated 'Locations' section, adding Ontario and Quebec sites and removing the previous separate state/location blocks.
    Difference
    1%
    Check dated 2025-12-17T22:41:56.000Z thumbnail image

Stay in the know with updates to SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.